We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Blood Tests Differentiate Myocardial Injury from Infarction

By LabMedica International staff writers
Posted on 03 Oct 2018
Print article
Image: An illustration of early cardiac troponin kinetics in patients after acute myocardial injury including acute myocardial infarction (Photo courtesy of ESC Scientific Document Group).
Image: An illustration of early cardiac troponin kinetics in patients after acute myocardial injury including acute myocardial infarction (Photo courtesy of ESC Scientific Document Group).
Myocardial infarction represents the death of myocardial cells and is characterized by acute myocardial ischemia. Nonischemic myocardial injury by comparison is often associated with other conditions such as renal failure or heart conditions like myocarditis.

A new definition of acute myocardial infarction (MI) that separates it from myocardial injury presents an opportunity for laboratories to fully leverage high-sensitivity cardiac troponin (hs-cTn) assays and provide better guidance to physicians on interpreting cTn results.

An international team of experts led by a specialist at the Aarhus University Hospital (Aarhus, Denmark) have issued the Fourth Universal Definition of MI and also commented on multiple approaches that use early data to predict who will have an acute MI and who will rule out. The document lists these various screening and triage approaches for rapid rule in and rule out, listing some of the pros and cons of each approach.

Biomarkers cTn I and T help define who has acute MI. Myocardial injury reflects an elevated cTn value above the 99th percentile upper reference limit. When cTn values rise and fall due to myocardial ischemia with at least one value exceeding the 99th percentile, then the definition changes to acute MI. The advent of hs-cTn assays underscores the need to create this differentiation between heart attack and injury.

Clinical laboratory scientists in the wake of this new definition could take several measures to help physicians appropriately use and interpret hs-cTn results. Consistent use of the 99th percentile protocol is one such approach. Laboratories sometimes decide that the 99th percentile is something else and use their own cutoffs. This undermines the guidance the Universal Fourth Definition is trying to achieve.

Laboratories also need to work on turnaround time to prevent emergency department overcrowding as when the emergency department is overloaded, all patients suffer. Allan Jaffe, MD, a cardiologist and guideline co-author, said, “It’s hard to suggest approaches to evaluate changing patterns or results or when to consider other possibilities when these are set up as if one is using the assays properly and someone else is using different cutoffs. Then it doesn’t work well. It’s important that labs start to come together and stop deciding that the 99th percentile is something else.” The study was published on August 28, 2018, in the European Heart Journal.

Related Links:
Aarhus University Hospital

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.